View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharma Mar 배당 및 자사주 매입배당 기준 점검 2/6Pharma Mar 수익으로 충분히 충당되는 현재 수익률 1.96% 보유한 배당금 지급 회사입니다.핵심 정보2.0%배당 수익률-1.2%자사주 매입 수익률총 주주 수익률0.8%미래 배당 수익률2.0%배당 성장률10.8%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향24%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).모든 업데이트 보기Recent updates공고 • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025공고 • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024공고 • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.공고 • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024공고 • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.공고 • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.공고 • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, PHM1 N 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: PHM1 N 의 배당금 지급이 증가했지만 회사는 3 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Pharma Mar 배당 수익률 vs 시장PHM1 N의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PHM1 N)2.0%시장 하위 25% (MX)0%시장 상위 25% (MX)0%업계 평균 (Biotechs)0%분석가 예측 (PHM1 N) (최대 3년)2.0%주목할만한 배당금: PHM1 N 의 배당금( 1.96% )은 MX 시장에서 배당금 지급자의 하위 25%( 2.29% )와 비교해 주목할 만하지 않습니다.고배당: PHM1 N 의 배당금( 1.96% )은 MX 시장에서 배당금 지급자의 상위 25%( 5.95% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 23.8% )이 낮기 때문에 PHM1 N 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 39.9% )로 PHM1 N 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YMX 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/12 01:11종가2023/03/16 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharma Mar, S.A.는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jaime EscribanoBanco SantanderPatricia CifuentesBestinver Sociedad De Valores, S.AKambiz YazdiBTIG9명의 분석가 더 보기
Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).
공고 • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025
공고 • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024
공고 • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.
공고 • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024
공고 • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.
공고 • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.
공고 • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.
Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).